Dyskinesia PRIORITY AREA
Why Is Dyskinesia a Priority?
To replace the progressive loss of dopamine-producing neurons, and minimize the resulting motor symptoms, Parkinson's patients are most commonly treated with the drug levodopa. Unfortunately, after repeated use of levodopa, the vast majority of patients eventually develop levodopa-induced dyskinesia (LID), highly disabling involuntary movements. Whether due to underlying brain circuit changes induced by levodopa, or its pulsatile or inappropriate delivery to the brain, LIDs significantly reduce overall quality of life for Parkinson's patients
Our Investment in Dyskinesia Research
The Michael J. Fox Foundation has supported multiple efforts to better understand, control and prevent the mechanisms responsible for the development of LID. These include:
- Identifying novel biological targets and therapeutic approaches.
- Generating and validating critical tools, including developing a dyskinesia clinical rating scale for use in therapeutic trials
- Develop approaches to enable more continuous delivery of L-DOPA to maximize symptomatic benefit for Parkinson's disease while limiting drug-induced side effects, such as motor fluctuations and dyskinesia.
Accelerate Your Research
Access Research Tools
Select from pre-clinical models, reagents, research data and more.
Sign-up for Emails
Receive regular updates on funding opportunities and other resources.